Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study ...

They’re in their 60s and still paying off student loans. College debt in America now lasts a lifetime.

I just keep hoping that it will just magically go away or I’ll just die”: A growing feature of the nation’s $1.7 trillion ...